1. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood 89:3909-3918, 1997.

Genomic alterrations and survival in chronic lymphocytic leukemia. N Engl J Med 343:1910-1916, 2000.

3. Hamblin TJ, Davis Z, Gardiner A, et al.: Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94:1848-1854, 1999.

4. Damle RN, Wasil T, Fais F, et al.: Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94: 1840-1847, 1999.

5. Argatoff LH, Connors JM, Klasa RJ, et al.: Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997.

6. Ott G, Kalla J, Hanke A, et al.: The cytomorphological spectrum of mantle cell lymphoma is reflected by distinct biological features. Leuk Lymphoma 32:55-63, 1998.

7. Diaz de Leon E, Alkan S, Huang JC, et al.: Utility of an immunohistochemical panel (CD5, CD10, CD20, CD23, CD43, and Cyclin D1) in parafffin-embedded tissues for the differentiation fo b-cell non-Hodgkin's lymphomas of small lymphocytes. Mod Pathol 11: 1046-1051, 1998.

8. Fu K, Weisenburger DD, Greiner TC, et al.: Cyclin D1-negative mantle cell lymphoma: a study of 9 cases. Mod Pathol 17:248A, 2004.

9. Greiner TC, Moynihan MJ, Chan WC, et al.: p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 87:4302-4310, 1996.

10. Ott G, Kalla J, Ott MM, et al.: Blastoid variants of mantle cell lymphoma—frequent bcl-1 rearrangements at the major translocation cluster regions and tetraploid chromosome clones. Blood 89:1421-1429, 1997.

11. Pinyol M, Hernandez L, Cazorla M, et al.: Deletions and loss of expression of p16(ink4a) and p21(waf1) genes are associated with aggressive variants of mantle cell lymphomas. Blood 89:272-280, 1997.

12. Mann RB, Berard CW: Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method. Hematol Oncol 1:187-192, 1983.

13. Chau I, Jones R, Cunningham D, et al.: Outcome of fol-licular lymphoma grade 3: is anthracycline necessary as front-line therapy? Br J Cancer 89:36-42, 2003.

14. Jaffe ES, Harris NL, Stein H, et al.: Tumours of Haematopoeitic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

15. Hans CP, Weisenburger DD, Vose JM, et al.: A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood 101:2363-2367, 2003.

16. Ngan B, Warnke A, Cleary ML: Variability of immunoglobulin expression in follicular lymphoma. An immunohistologic and molecular genetic study. Am J Pathol 135:1139-1144, 1989.

17. Raible MD, Hsi ED, Diaz de Leon E, et al.: bcl-6 protein expression in follicle center cell lymphomas: a marker for distinguishing these lymphomas from other low grade-lymphoproliferative disorders. Am J Clin Pathol 112:101-107, 1999.

18. Gaulard P, d'Agay MF, Peuchmaur M, et al.: Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol 140:1089-1095, 1992.

19. Horsman DE, Gascoyne RD, Coupland RW, et al.: Comparison of cytogenetic analysis, southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma. Am J Clin Pathol 103:472-478, 1995.

20. Seto M, Jaeger U, Hockett RD, et al.: Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 7:123-131, 1988.

21. Albinger-Hegyi A, Hochreutener B, Abdou MT, et al.: High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection. Am J Pathol 160:823-832, 2002.

22. Vaandrager JW, Schuuring E, Raap T, et al.: Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes. Genes Chromosomes Cancer 27:85-94, 2000.

23. Mirza I, Macpherson N, Paproski S, et al.: Primary cutaneous follicular lymphoma: an assessment of clinical, histopathologic, immunophenotypic, and molecular features. J Clin Oncol 20:647-655, 2002.

24. Lorsbach RB, Shay-Seymore D, Moore J, et al.: Clinicopathologic analysis of follicular lymphoma occurring in children. Blood 99:1959-1964, 2002.

25. Thieblemont C, Bastion Y, Berger F, et al.: Mucosa-associated lymphoid tissue gastrointestinal and non-gastrointestinal lymphoma behavior: analysis of 108 patients. J Clin Onco 15:1624-1630, 1997.

26. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, et al.: Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma. Lancet 338:1175-1176, 1991.

27. Hussell T, Isaacson PG, Crabtree JE, et al.: Helicobacter pylori-specific tumour-infiltrating T cells provide contact dependent help for the growth of malignant B cells in low- grade gastric lymphoma of mucosa-associated lymphoid tissue. J Pathol 178:122-127, 1996.

28. Hussell T, Isaacson PG, Crabtree JE, Spencer J: The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 342:571-574, 1993.

29. Greiner A, Marx A, Heesemann J, et al.: Idiotype identity in a MALT-type lymphoma and B cells in Helicobacter pylori associated chronic gastritis. Lab Invest 70:572-578, 1994.

30. Fischbach W, Goebeler-Kolve ME, Dragosics B, et al.: Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 53:34-37, 2004.

31. Thieblemont C, Berger F, Dumontet C, et al.: Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed Blood 95:802-806, 2000. [Erratum, Blood 95(8):2481, 2000].

32. Hsi ED, Zukerberg LR, Schnitzer B, et al.: Development of extrasalivary gland lymphoma in myoepithelial sialadenitis. Mod Pathol 8:817-824, 1995.

33. Liu H, Ye H, Dogan A, et al.: T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 98:1182-1187, 2001.

34. Remstein ED, James CD, Kurtin PJ: Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 156:1183-1188, 2000.

35. Ye H, Liu H, Attygalle A, et al.: Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 102:1012-1018, 2003.

36. Zhou H, Du MQ, Dixit VM: Constitutive NF-kappaB activation by the t(11;18)(q21;q21) product in MALT lymphoma is linked to deregulated ubiquitin ligase activity. Cancer Cell 7:425-431, 2005.

37. Streubel B, Lamprecht A, Dierlamm J, et al.: T(14;18)(q32;q21) involving IGH and MALT1 is a frequent chromosomal aberration in MALT lymphoma. Blood 101:2335-2339, 2003.

38. Cavalli F, Isaacson PG, Gascoyne RD, et al.: MALT Lymphomas. Hematology 241-258, 2001.

39. Mulligan SP, Matutes E, Dearden C, et al.: Splenic lymphoma with villous lymphocytes: natural history and response to therapy in 50 cases. Br J Haematol 78: 206-209, 1991.

40. Melo JV, Hegde U, Parreira A, et al.: Splenic B cell lymphoma with circulating villous lymphocytes: differential diagnosis of B cell leukaemias with large spleens.

J Clin Pathol 40:642-651, 1987.

41. Hammer RD, Glick AD, Greer JP, et al.: Splenic marginal zone lymphoma. A distinct B-cell neoplasm. Am J SurgPathol 20:613-626, 1996.

42. Isaacson PG, Matutes E, Burke M, et al.: The histopathol-ogy of splenic lymphoma with villous lymphocytes. Blood 84:3828-3834, 1994.

43. Costes V, Duchayne E, Taib J, et al.: Intrasinusoidal bone marrow infiltration: a common growth pattern for different lymphoma subtypes. Br J Haematol 119: 916-922, 2002.

44. Labouyrie E, Marit G, Vial JP, et al.: Intrasinusoidal bone marrow involvement by splenic lymphoma with villous lymphocytes: a helpful immunohistologic feature. Mod Pathol 10:1015-1020, 1997.

45. Matutes E, Morilla R, Owusu-Ankomah K, et al.: The immunophenotype of splenic lymphoma with villous lymphocytes and its relevance to the differential diagnosis with other B-cell disorders. Blood 83:1558-1562, 1994.

46. Lima M, dos Anjos Teixeira M, Queiros ML, et al.: BCL-2 oncoprotein (p26) in splenic lymphoma with villous lymphocytes: a comparative study with other chronic B-cell disorders. Am JHematol 56:122-125, 1997.

47. Gruszka-Westwood AM, Hamoudi R, Osborne L, et al.: Deletion mapping on the long arm of chromosome 7 in splenic lymphoma with villous lymphocytes. Genes Chromosomes Cancer 36:57-69, 2003.

48. Sole F, Salido M, Espinet B, et al.: Splenic marginal zone B-cell lymphomas: two cytogenetic subtypes, one with gain of 3q and the other with loss of 7q. Haematologica 86:71-77, 2001.

49. Remstein ED, James CD, Kurtin PJ: Incidence and subtype specificity of API2-MALT1 fusion translocations in extranodal, nodal, and splenic marginal zone lymphomas. Am J Pathol 156:1183-1188, 2000.

50. Algara P, Mateo MS, Sanchez-Beato M, et al.: Analysis of the IgV(H) somatic mutations in splenic marginal zone lymphoma defines a group of unmutated cases with frequent 7q deletion and adverse clinical course. Blood 99:1299-1304, 2002.

51. Campo E, Miquel R, Krenacs L, et al.: Primary nodal marginal zone lymphomas or splenic and MALT type. Am J Surg Pathol 23(1):59-68, 1999.

52. Cook JR, Aguilera NI, Reshmi-Skarja S, et al.: Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum Pathol 35:447-454, 2004.

53. Fisher RI, Gaynor ER, Dahlberg S, et al.: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993.

54. Li S, Eshleman JR, Borowitz MJ: Lack of surface immunoglobulin light chain expression by flow cyto-metric immunophenotyping can help diagnose peripheral B-cell lymphoma. Am J Clin Pathol 118:229-234, 2002.

55. Gascoyne RD, Adomat SA, Krajewski S, et al.: Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphoma. Blood 90:244-251, 1997.

56. Miller TP, Grogan TM, Dahlberg S, et al.: Prognostic significance of the Ki-67-associated proliferative antigen in aggressive non-Hodgkin's lymphomas: a prospective Southwest Oncology Group trial. Blood 83:1460-1466, 1994.

57. Lossos IS, Jones CD, Warnke R, et al.: Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood 98:945-951, 2001.

58. Hans CP, Weisenburger DD, Greiner TC, et al.: Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103:275-282, 2004.

59. Huang JZ, Sanger WG, Greiner TC, et al.: The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 99:2285-2290, 2002.

60. Lo Coco F, Ye BH, Lista F, et al.: Rearrangements of the BCL6 gene in diffuse large cell non- Hodgkin's lymphoma. Blood 83:1757-1759, 1994.

61. Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403:503-511, 2000.

62. Rosenwald A, Wright G, Chan WC, et al.: The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 346:1937-1947, 2002.

63. Shipp MA, Ross KN, Tamayo P, et al.: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 8:68-74, 2002.

64. Lossos IS, Czerwinski DK, Alizadeh AA, et al.: Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 350:1828-1837, 2004.

65. Levine AM, Seneviratne L, Espina BM, et al.: Evolving characteristics of AIDS-related lymphoma. Blood 96:4084-4090, 2000.

66. Diebold J, Raphael M, Prevot S, et al.: Lymphomas associated with HIV infection. Cancer Surv 30:263-293, 1997.

67. Neri A, Barriga F, Knowles DM, et al.: Different regions of the immunoglobulin heavy-chain locus are involved in chromosomal translocations in distinct pathogenetic forms of Burkitt lymphoma. Proc Natl Acad Sci USA 85:2748-2752, 1988.

68. Neri A, Barriga F, Inghirami G, et al.: Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma. Blood 77:1092-1095, 1991.

69. Nicholson AG, Wotherspoon AC, Diss TC, et al.: Lymphomatoid granulomatosis - evidence that some cases represent epstein-barr virus-associated b-cell lymphoma. Histopathology 29:317-324, 1996.

70. Haque AK, Myers JL, Hudnall SD, et al.: Pulmonary lymphomatoid granulomatosis in acquired immunodeficiency syndrome: lesions with Epstein-Barr virus infection. Mod Pathol 11:347-356, 1998.

71. Ilowite NT, Fligner CL, Ochs HD, et al.: Pulmonary angiitis with atypical lymphoreticular infiltrates in Wiskott-Aldrich syndrome: possible relationship of lymphomatoid granulomatosis and EBV infection. Clin Immunol Immunopathol 41:479-484, 1986.

72. Cohen ML, Dawkins RL, Henderson DW, et al.: Pulmonary lymphomatoid granulomatosis with immunodeficiency terminating as malignant lymphoma. Pathology 11:537-550, 1979.

73. Jaffe ES, Wilson WH: Lymphomatoid granulomatosis: pathogenesis, pathology and clinical implications. Cancer Surv 30:233-248, 1997.

74. Lipford EH, Jr, Margolick JB, Longo DL, et al.: Angiocentric immunoproliferative lesions: a clinico-pathologic spectrum of post-thymic T-cell proliferations. Blood 72:1674-1681, 1988.

75. Guinee DG Jr, Perkins SL, Travis WD, et al.: Proliferation and cellular phenotype in lymphomatoid granulomatosis: implications of a higher proliferation index in B cells. Am J Surg Pathol 22:1093-1100, 1998.

76. Guinee D, Jr, Jaffe E, Kingma D, et al.: Pulmonary lym-phomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 18:753-764, 1994.

77. Ansari MQ, Dawson DB, Nador R, et al.: Primary body cavity-based AIDS-related lymphomas. Am J Clin Pathol 105:221-229, 1996.

78. Nador RG, Cesarman E, Chadburn A, et al.: Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood 88:645-656, 1996.

79. Cannon ML, Cesarman E: The KSHV G protein-coupled receptor signals via multiple pathways to induce transcription factor activation in primary effusion lymphoma cells. Oncogene 23:514-523, 2004.

80. An J, Sun Y, Rettig MB: Transcriptional coactivation of c-Jun by the KSHV-encoded LANA. Blood 103:222-228, 2004.

81. An J, Sun Y, Sun R, et al.: Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene 22:3371-3385, 2003.

82. Cesarman E, Nador RG, Bai F, et al.: Kaposi's sarcoma-associated herpesvirus contains G protein-coupled receptor and cyclin D homologs which are expressed in

Kaposi's sarcoma and malignant lymphoma. J Virol 70:8218-8223, 1996.

83. Ralfkiaer E, Muller-Hermelink HK, Jaffe ES: Peripheral T-cell lymphoma, unspecified. In: Jaffe ES, Harris NL, Stein H, et al. (eds.) Tumours of the Haematopoietic and Lymphoid Tissues. Lyons, France: IARC Press; 2001.

84. Zettl A, Rudiger T, Konrad MA, et al.: Genomic profiling of peripheral T-cell lymphoma, unspecified, and anaplastic large T-cell lymphoma delineates novel recurrent chromosomal alterations. Am J Pathol 164:1837-1848, 2004.

85. Delsol G, Ralfkiaer E, Stein H, et al.: Anaplastic large cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. (eds.) Tumours of the Haematopoietic and Lymphoid System. Lyon, France: IARC Press; 2001.

86. Falini B, Pileri S, Zinzani PL, et al.: ALK+ lymphoma: clinico-pathological findings and outcome. Blood 93:2697-2706, 1999.

87. Lae ME, Ahmed I, Macon WR: Clusterin is widely expressed in systemic anaplastic large cell lymphoma but fails to differentiate primary from secondary cutaneous anaplastic large cell lymphoma. Am J Clin Pathol 118:773-779, 2002.

88. Wellmann A, Thieblemont C, Pittaluga S, et al.: Detection of differentially expressed genes in lymphomas using cDNA arrays: identification of clusterin as a new diagnostic marker for anaplastic large-cell lymphomas. Blood 96:398-404, 2000.

89. Drexler HG, Gignac SM, von Wasielewski R, et al.: Pathobiology of NPM-ALK and variant fusion genes in anaplastic large cell lymphoma and other lymphomas. Leukemia 14:1533-1559, 2000.

90. Cataldo KA, Jalal SM, Law ME, et al.: Detection of t(2;5) in anaplastic large cell lymphoma: comparison of immunohistochemical studies, FISH, and RT-PCR in paraffin-embedded tissue. Am J Surg Pathol 23:1386-1392, 1999.

91. Jaffe E, Ralfkiaer E: Angioimmunoblastic T-cell lymphoma. In: Jaffe E, Harris N, Stein H, et al. (eds.) Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

92. Ferry JA: Angioimmunoblastic T-cell lymphoma. Adv Anat Pathol 9:273-279, 2002.

93. Attygalle A, Al Jehani R, Diss TC, et al.: Neoplastic T cells in angioimmunoblastic T-cell lymphoma express CD10. Blood 99:627-633, 2002.

94. Attygalle A, Diss TC, Isaacson PG, et al.: CD10 expression in extranodal dissemination of angioimmunoblas-tic T-cell lymphoma. Am J Surg Pathol 15:964, 2002.

95. Lepretre S, Buchonnet G, Stamatoullas A, et al.: Chromosome abnormalities in peripheral T-cell lymphoma. Cancer Genet Cytogenet 117:71-79, 2000.

96. Isaacson PG, Wright D, Ralfkiaer E, et al.: Enteropathy-type T-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. (eds.) Tumours of Haematopoietic and Lymphoid Tissues. Lyons, France: IARC Press; 2001.

97. Chott A, Dragosics B, Radaszkiewicz T: Peripheral T-cell lymphomas of the intestine. Am J Pathol 141:1361-1371, 1992.

98. Spencer J, Cerf-Bensussan N, Jarry A, et al.: Enteropathy-associated T cell lymphoma (malignant histiocytosis of the intestine) is recognized by a monoclonal antibody (HML-1) that defines a membrane molecule on human mucosal lymphocytes. Am J Pathol 132:1-5, 1988.

99. Chott A, Haedicke W, Mosberger I, et al: Most CD56+ intestinal lymphomas are CD8+CD5-T-cell lymphomas of monomorphic small to medium size histology. Am J Pathol 153:1483-1490, 1998.

100. Bagdi E, Diss TC, Munson P, et al.: Mucosal intra-epithelial lymphocytes in enteropathy-associated T-cell lymphoma, ulcerative jejunitis, and refractory celiac disease constitute a neoplastic population. Blood 94:260-264, 1999.

101. Howell WM, Leung ST, Jones DB, et al.: HLA-DRB, -DQA, and -DQB polymorphism in celiac disease and enteropathy-associated T-cell lymphoma. Common features and additional risk factors for malignancy. Hum Immunol 43:29-37,1995.

102. Chan JKC, Jaffe ES, Ralfkiaer E: Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, et al. (eds.) Tumours of the Haematopoietc and Lymphoid System. Lyons, France: IARC Press, 2001.

103. Cheung MM, Chan JK, Wong KF: Natural killer cell neoplasms: a distinctive group of highly aggressive lym-phomas/leukemias. Semin Hematol 40:221-232, 2003.

104. Kinney MC: The role of morphologic features, pheno-type, genotype, and anatomic site in defining extranodal T-cell or NK-cell neoplasms. Am J Clin Pathol 111:S104-S118, 1999.

105. Chan JK, Sin VC, Wong KF, et al.: Nonnasal lymphoma expressing the natural killer cell marker CD56: a clini-copathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 89:4501-4513, 1997.

106. Martin AR, Chan WC, Perry DA, et al.: Aggressive natural killer cell lymphoma of the small intestine. Mod Pathol 8:467-472, 1995.

107. Petrella T, Delfau-Larue MH, Caillot D, et al.: Nasopharyngeal lymphomas: further evidence for a natural killer cell origin. Hum Pathol 27:827-833, 1996.

108. Wong KF, Zhang YM, Chan JK: Cytogenetic abnormalities in natural killer cell lymphoma/leukaemia-is there a consistent pattern? Leuk Lymphoma 34:241-250, 1999.

109. Jaffe E, Harris N, Stein H, et al.: Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.

110. Belhadj K, Reyes F, Farcet JP, et al.: Hepatosplenic gam-madelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. Blood 102:4261-4269, 2003.

111. Vega F, Medeiros LJ, Bueso-Ramos C, et al.: Hepatosplenic gamma/delta T-cell lymphoma in bone marrow. A sinusoidal neoplasm with blastic cytologic features. Am J Clin Pathol 116:410-419, 2001.

112. Macon WR, Levy NB, Kurtin PJ, et al.: Hepatosplenic alphabeta T-cell lymphomas: a report of 14 cases and comparison with hepatosplenic gammadelta T-cell lymphomas. Am J Surg Pathol 25:285-296, 2001.

113. Ralfkiaer E, Jaffe ES: Mycosis fungoides and Sezary syndrome. In: Jaffe ES, Harris NL, Stein H, et al. (eds.) Tumours of the Haematopoietic and Lymphoid Tissues. Lyons, France: IARC Press; 2001.

114. Willemze R, Kerl H, Sterry W, et al.: EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 90:354-371, 1997.

115. Colby TV, Burke JS, Hoppe RT: Lymph node biopsy in mycosis fungoides. Cancer 47:351-359, 1981.

116. Scheffer E, Meijer CJ, van Vloten WA: Dermatopathic lymphadenopathy and lymph node involvement in mycosis fungoides. Cancer 45:137-148, 1980.

117. Thangavelu M, Finn WG, Yelavarthi KK, et al.: Recurring structural chromosome abnormalities in peripheral blood lymphocytes of patients with mycosis fungoides/Sezary syndrome. Blood 89:3371-3377, 1997.

118. Mao X, Lillington D, Scarisbrick JJ, et al.: Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol 147:464-475, 2002.

119. Ralfkiaer E, Delsol G, Willemze R, et al.: Primary cutaneous CD30-positive T-cell lymphoproliferative disorders. In: Jaffe ES, Harris NL, Stein H, et al. (eds.) Tumours of the Haematopoietic and Lymphoid Tissues. Lyons, France: IARC Press; 2001.

120. Willemze R, Meijer CJ: Primary cutaneous CD30-positive lymphoproliferative disorders. Hematol Oncol Clin North Am 17:1319-1332, 2003.

121. Kadin ME, Carpenter C: Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol 40:244-256, 2003.

122. Weiss LM, Wood GS, Trela M, et al.: Clonal T-cell populations in lymphomatoid papulosis. Evidence of a lym-phoproliferative origin for a clinically benign disease. N Engl J Med 315:475-479, 1986.

123. Steinhoff M, Hummel M, Anagnostopoulos I, et al.: Single-cell analysis of CD30+ cells in lymphomatoid papulosis demonstrates a common clonal T-cell origin. Blood 100:578-584, 2002.

124. Jaffe ES, Ralfkiaer E: Subcutaneous panniculitis-like T-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. (eds.) Tumours of Haematopoietic and Lymphoid Tissues. Lyons, France: IARC Press; 2001.

125. Jaffe ES, Krenacs L, Raffeld M: Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 40:175-184, 2003.

126. Santucci M, Pimpinelli N, Massi D, et al.: Cytotoxic/ natural killer cell cutaneous lymphomas. Report of eortc cutaneous lymphoma task force workshop. Cancer 97:610-627, 2003.

127. Willemze R, Jaffe ES, Burg G, et al.: WHO-EORTC classification for cutaneous lymphomas. Blood 105:3768-3785, 2005.

128. Chan JKC, Jaffe ES, Ralfkiaer E: Blastic NK-cell lymphoma. In: Jaffe ES, Harris NL, Stein H, et al. (eds.) Tumours of the Haematopoietic and Lymphoid Tissues. Lyons, France: IARC Press; 2001.

129. Bene MC, Feuillard J, Jacob MC: Plasmacytoid dendritic cells: from the plasmacytoid T-cell to type 2 dendritic cells CD4+CD56+ malignancies. Semin Hematol 40:257-266, 2003.

130. Feuillard J, Jacob MC, Valensi F, et al.: Clinical and biologic features of CD4(+)CD56(+) malignancies. Blood 99:1556-1563, 2002.

131. Jacob MC, Chaperot L, Mossuz P, et al.: CD4+ CD56+ lineage negative malignancies: a new entity developed from malignant early plasmacytoid dendritic cells. Haematologica 88:941-955, 2003.

0 0

Post a comment